GlassScriptPhysician profile
Navin P Wadehra
NPI 1396755385
$1,855.69
in general payments reported to CMS, 2019-2025
32 companies · $290 in 2025
The $290 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2020: $162 · 2021: $251 · 2022: $189 · 2023: $235 · 2024: $401 · 2025: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $880 · Education: $46.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $879.58 |
| Education | $46.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $205.49 | 2019-2025 | |
| Pfizer INC. | $200.86 | 2019-2025 | |
| Janssen Biotech, INC. | $166.44 | 2019-2025 | Darzalex, Tecvayli, Imbruvica |
| Merck Sharp & Dohme LLC | $161.96 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Amgen INC. | $123.39 | 2020-2023 | Blincyto, Kyprolis |
| Daiichi Sankyo INC. | $105.98 | 2024-2025 | Enhertu |
| Abbvie INC. | $100.34 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $74.90 | 2021-2024 | |
| Seagen INC. | $73.37 | 2019-2023 | Adcetris |
| E.R. Squibb & Sons, L.L.C. | $60.63 | 2019 | |
| Genentech USA, INC. | $56.76 | 2019-2023 | Venclexta |
| Pharmacyclics LLC, An Abbvie Company | $40.86 | 2021-2022 | |
| Mirati Therapeutics, INC. | $40.51 | 2023 | Krazati |
| Bayer Healthcare Pharmaceuticals INC. | $39.91 | 2022 | |
| Coherus Oncology, INC. | $39.51 | 2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $37.78 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.24 | 2024 | Iclusig |
| Epizyme, INC. | $34.21 | 2021 | |
| Stemline Therapeutics INC. | $28.43 | 2025 | Orserdu |
| Pharmaessentia USA Corporation | $28.41 | 2025 | Besremi |
| Glaxosmithkline, LLC. | $23.48 | 2021 | |
| Gilead Sciences, INC. | $22.59 | 2023 | Trodelvy |
| Rigel Pharmaceuticals, INC. | $20.45 | 2023 | Tavalisse, Rezlidhia |
| Karyopharm Therapeutics INC. | $19.10 | 2021 | |
| Eisai INC. | $17.19 | 2024 | |
| Array Biopharma INC | $16.01 | 2021 | |
| Morphosys, US INC. | $15.25 | 2022 | |
| Lilly USA, LLC | $15.07 | 2020 | |
| Puma Biotechnology, INC. | $14.56 | 2021 | |
| Kite Pharma, INC. | $13.13 | 2022 | |
| Taiho Oncology, INC. | $12.98 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.90 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Navin Wadehra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.